🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

François‐Clément Bidard

ORCID: 0000-0001-5932-8949

Also affiliated with Université de Versailles Saint-Quentin-en-Yvelines, Université Paris-Saclay, Institut Curie

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial”.

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

Annals of Oncology(2023)10.1016/j.annonc.2023.08.003

N/A

1.4DataRank · unranked

61 citations

L.D. Eli, Hans Wildiers, Sara A. Hurvitz, Ángel Guerrero‐Zotano, Nisha Unni +37 more

Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa113

N/A

0DataRank · unranked

48 citations

Laura H. Hendrix, Terry Hyslop, William T. Barry, Eric P. Winer, Clifford A. Hudis +27 more

Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells

Breast Cancer Research and Treatment(2023)10.1007/s10549-023-06998-w

N/A

0DataRank · unranked

6 citations

Aditya Bardia, Brian Chirn, Brittany A. Reeves, Joseph A. LiCausi, Risa Burr +18 more